Quarterly report pursuant to Section 13 or 15(d)

Non-controlling Interest (Details)

v3.19.3
Non-controlling Interest (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 05, 2018
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Noncontrolling Interest [Line Items]                    
Net Loss Attributable to Non-controlling Interest   $ (30,000) $ (27,000) $ (16,000) $ (9,000) $ (16,000) $ (9,000) $ (73,000) $ (35,000)  
Stockholders' Equity Attributable to Noncontrolling Interest   (2,841,000)           (2,841,000)   $ (2,909,000)
Related Party Transaction, Expenses from Transactions with Related Party $ 441,000                  
Research and Development Expense   $ 4,144,000     $ 2,846,000     $ 9,156,000 $ 9,788,000  
Cedarssinai Medical Center [Member]                    
Noncontrolling Interest [Line Items]                    
Number Of Common Stock To Be Issued 50,000 50,000           50,000    
Research and Development Expense   $ 108,000           $ 318,000    
Fair Value Of Shares Issued $ 285,000